Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 Current Ratio is 1.58 as of Mar. 2025, which is 32% above its 10-year median of 1.20. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 73.51% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Avience Biomedicals's current ratio for the quarter that ended in Mar. 2025 was 1.58.
Avience Biomedicals has a current ratio of 1.58. It generally indicates good short-term financial strength.
The historical rank and industry rank for Avience Biomedicals's Current Ratio or its related term are showing as below:
NSE:AVIENCE'
s Current Ratio Range Over the Past 10 Years
Min: 1.11 Med: 1.2 Max: 1.58
Current: 1.58
During the past 3 years, Avience Biomedicals's highest Current Ratio was 1.58. The lowest was 1.11. And the median was 1.20.
NSE:AVIENCE's Current Ratio is ranked worse than 73.51% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs NSE:AVIENCE: 1.58
Avience Biomedicals (NSE:AVIENCE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Avience Biomedicals Current Ratio Related Terms
Avience Biomedicals Current Ratio Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals Current Ratio Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
Current Ratio
1.20
1.11
1.58
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
Current Ratio
1.20
1.11
1.58
NSE:AVIENCE vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Avience Biomedicals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals (NSE:AVIENCE) has a Current Ratio of 1.58 as of Mar. 2025. This is 32% above median its historical median of 1.20. Over the past decade, Avience Biomedicals' Current Ratio has ranged from 1.11 to 1.58. According to the industry distribution chart, Avience Biomedicals ranks #627 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 73.5%.
Is Avience Biomedicals' Current Ratio too high?
Avience Biomedicals' current Current Ratio of 1.58 is 32% above median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 1.58. The Medical Devices & Instruments industry median Current Ratio is 2.49. Avience Biomedicals' value of 1.58 is 36.5% below this industry median. Based on the distribution chart, Avience Biomedicals ranks #627 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #627 out of 853 companies for Current Ratio. This places Avience Biomedicals in the lower half of its industry. The industry median Current Ratio is 2.49. Avience Biomedicals' value of 1.58 is 36.5% below this benchmark. Historically, Avience Biomedicals' own Current Ratio has ranged from 1.11 to 1.58 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 2.49, Avience Biomedicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current Current Ratio of 1.58 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current Current Ratio is 1.58, which is 32% above median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Current Ratio of 1.58. The current Current Ratio is 1.58, which is 32% above median its 10-year median of 1.20 and 36.5% below the Medical Devices & Instruments industry median of 2.49. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Current Ratio is 1.58 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
